Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
260
Trial Sponsor
Clinical Trial Start Date
2004
0Primary Completion Date
2008
0Study Completion Date
2008
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Interventional Trial Phase
Phase 20
Phase 10
Participating Facility
Official Name
A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma0
Last Updated
February 18, 2013
0Allocation Type
Non-Randomized0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
MB-0020
Study summary
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
